Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects.

comprehensive geriatric assessment elderly patients glioblastoma molecular factors prognostic factors

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
10 Mar 2022
Historique:
received: 13 02 2022
revised: 07 03 2022
accepted: 08 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

Glioblastoma (GBM) is the most aggressive primary brain tumour. As GBM incidence is associated with age, elderly people represent a consistent subgroup of patients. Elderly people with GBM show dismal prognosis (about 6 months) and limited response to treatments. Age is a negative prognostic factor, which correlates with clinical frailty, poorer tolerability to surgery or adjuvant radio-chemotherapy, and higher occurrence of comorbidities and/or secondary complications. The aim of this paper is to review the clinical and molecular characteristics, current therapeutic options, and prognostic factors of elderly patients with GBM.

Identifiants

pubmed: 35327445
pii: biomedicines10030644
doi: 10.3390/biomedicines10030644
pmc: PMC8945166
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Nucleic Acids Res. 2008 Jan;36(Database issue):D842-6
pubmed: 17932060
Clin Oncol (R Coll Radiol). 2017 Nov;29(11):739-747
pubmed: 28807361
Oncol Rep. 2005 Dec;14(6):1583-8
pubmed: 16273260
Cancer. 2009 Aug 15;115(16):3758-66
pubmed: 19484785
Neurosurgery. 2018 Jan 1;82(1):64-75
pubmed: 28475720
J Neurooncol. 2019 Oct;145(1):97-105
pubmed: 31456142
Neuro Oncol. 2014 Oct;16 Suppl 8:viii7-13
pubmed: 25342602
Neuro Oncol. 2018 Apr 9;20(5):608-620
pubmed: 29036500
Clin Cancer Res. 2018 Feb 15;24(4):737-743
pubmed: 28814435
Int J Cancer. 2018 Nov 15;143(10):2359-2366
pubmed: 30152087
J Clin Oncol. 2004 May 1;22(9):1583-8
pubmed: 15051755
Med Oncol. 2012 Dec;29(5):3467-71
pubmed: 22580816
Neuro Oncol. 2020 May 15;22(5):684-693
pubmed: 31747009
J Clin Oncol. 2015 Dec 10;33(35):4145-50
pubmed: 26392096
J Cancer Res Clin Oncol. 2015 Jun;141(6):1131-7
pubmed: 25577223
Ann Surg Oncol. 2011 Jan;18(1):239-45
pubmed: 20697823
Cancer. 2012 Nov 15;118(22):5595-600
pubmed: 22517216
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217
pubmed: 29075855
Oncologist. 2018 May;23(5):524-e44
pubmed: 29472310
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Neuro Oncol. 2011 Jan;13(1):84-98
pubmed: 20926426
J Clin Oncol. 2002 Jan 15;20(2):494-502
pubmed: 11786579
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
JCO Precis Oncol. 2019 Mar 27;3:
pubmed: 32914038
J Clin Oncol. 2018 Dec 10;36(35):3477-3484
pubmed: 30351999
Neuro Oncol. 2017 Apr 1;19(4):475-483
pubmed: 27852792
J Neurosurg. 2012 Feb;116(2):357-64
pubmed: 21942727
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
BMC Med Genomics. 2008 Oct 21;1:52
pubmed: 18940004
PLoS One. 2013 Apr 29;8(4):e62982
pubmed: 23658659
J Neurooncol. 2020 Sep;149(3):421-427
pubmed: 32989681
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31600898
J Clin Oncol. 2010 Jun 20;28(18):3061-8
pubmed: 20479398
Int J Mol Sci. 2020 Jan 23;21(3):
pubmed: 31979374
J Clin Oncol. 1984 Mar;2(3):187-93
pubmed: 6699671
N Engl J Med. 2007 Apr 12;356(15):1527-35
pubmed: 17429084
Neuro Oncol. 2019 Jan 1;21(1):95-105
pubmed: 30277538
Oncologist. 2019 Apr;24(4):529-536
pubmed: 30049883
J Clin Oncol. 2011 Aug 1;29(22):3050-5
pubmed: 21709196
Med Oncol. 2012 Dec;29(5):3478-83
pubmed: 22674154
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Neurochir (Wien). 2003 Jan;145(1):5-10
pubmed: 12545256
Clin Cancer Res. 2015 May 1;21(9):2057-64
pubmed: 25655102
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
J Clin Oncol. 2009 Mar 10;27(8):1268-74
pubmed: 19204207
Brain Tumor Pathol. 2020 Apr;37(2):50-59
pubmed: 32361941
Hum Mol Genet. 2011 Jul 15;20(14):2897-904
pubmed: 21531791
Nat Rev Neurol. 2010 Jan;6(1):39-51
pubmed: 19997073
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cancer Res. 2011 Mar 1;71(5):1647-57
pubmed: 21239473

Auteurs

Francesco Bruno (F)

Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science, 10126 Turin, Italy.

Alessia Pellerino (A)

Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science, 10126 Turin, Italy.

Rosa Palmiero (R)

Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science, 10126 Turin, Italy.

Luca Bertero (L)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Cristina Mantovani (C)

Division of Radiotherapy, Department of Oncology, University and City of Health and Science, 10126 Turin, Italy.

Diego Garbossa (D)

Division of Neurosurgery, Department of Neuroscience, University and City of Health and Science, 10126 Turin, Italy.

Riccardo Soffietti (R)

Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science, 10126 Turin, Italy.

Roberta Rudà (R)

Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science, 10126 Turin, Italy.
Department of Neurology, Castelfranco and Treviso Hospitals, 31100 Treviso, Italy.

Classifications MeSH